Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Complexo Hospitalario Universitario A Coruna, CHUAC, La Coruna, Spain.
Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany.
Eur J Heart Fail. 2016 Jun;18(6):613-25. doi: 10.1002/ejhf.566.
The European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT-R) was set up with the aim of describing the clinical epidemiology and the 1-year outcomes of patients with heart failure (HF) with the added intention of comparing differences between participating countries.
The ESC-HF-LT-R is a prospective, observational registry contributed to by 211 cardiology centres in 21 European and/or Mediterranean countries, all being member countries of the ESC. Between May 2011 and April 2013 it collected data on 12 440 patients, 40.5% of them hospitalized with acute HF (AHF) and 59.5% outpatients with chronic HF (CHF). The all-cause 1-year mortality rate was 23.6% for AHF and 6.4% for CHF. The combined endpoint of mortality or HF hospitalization within 1 year had a rate of 36% for AHF and 14.5% for CHF. All-cause mortality rates in the different regions ranged from 21.6% to 36.5% in patients with AHF, and from 6.9% to 15.6% in those with CHF. These differences in mortality between regions are thought reflect differences in the characteristics and/or management of these patients.
The ESC-HF-LT-R shows that 1-year all-cause mortality of patients with AHF is still high while the mortality of CHF is lower. This registry provides the opportunity to evaluate the management and outcomes of patients with HF and identify areas for improvement.
欧洲心脏病学会心力衰竭长期注册研究(ESC-HF-LT-R)旨在描述心力衰竭(HF)患者的临床流行病学和 1 年结局,并期望比较参与国家之间的差异。
ESC-HF-LT-R 是一项前瞻性、观察性注册研究,由 21 个欧洲和/或地中海国家的 211 个心脏病中心参与,这些中心均为 ESC 的成员国。该研究于 2011 年 5 月至 2013 年 4 月期间共纳入 12440 例患者,其中 40.5%为急性心力衰竭(AHF)住院患者,59.5%为慢性心力衰竭(CHF)门诊患者。AHF 患者的 1 年全因死亡率为 23.6%,CHF 患者为 6.4%。AHF 患者的 1 年内死亡或心力衰竭再住院的复合终点发生率为 36%,CHF 患者为 14.5%。不同地区的 AHF 患者全因死亡率从 21.6%到 36.5%不等,CHF 患者从 6.9%到 15.6%不等。这些地区间死亡率的差异反映了这些患者的特征和/或管理差异。
ESC-HF-LT-R 显示,AHF 患者 1 年全因死亡率仍然较高,而 CHF 死亡率较低。该注册研究为评估心力衰竭患者的管理和结局以及确定需要改进的领域提供了机会。